Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Mar
10
Today In Oncology
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks
FDA Releases Updated Guidance on Biosimilar Development
SABCS 2025: High-Level Review of Select Data
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo